March 27, 2017 12:52pm
… As the sector cuts its losses from the downside of the open
From five (5) down at the open to twenty eight (28) up of forty-three (43) covered
I follow the dictum, quoting Churchill that “short words are best, and the old words when short are best of all.”
How is your sector bracket doing ...
U.S. equities traded lower at Monday’s mid-day …
The NASDAQ is DOWN -1.57 or -0.03% to 5,827.13 and the DOW is DOWN -62.00 or -0.30% to 20,534.72.
A day in the life of the stem, cell, gene and regenerative therapy (SCGT & RT) sector – the advance/decline line scenario of our 43 covered companies:
- The open was negative with an A/DL of 35/5 and 3 flats;
- 10:00 am, the sector stayed negative with an A/DL of 19/21 and 3 flats;
- 11:00 am, the sector jumped positive with an A/DL of 30/11 and 2 flats;
- The mid-day continued positive with an A/DL of 28/12 and 3 flats;
From the pre-open’s investor’s letter title, “There are signals and there are indications.”
Reiterating, “The cell therapy sector should be recognizing a re-think their appeal to shareholder as many and more companies seek to access capital in the form of pre-offering depreciated share pricing and post financing onerous dilution of investor’s ownership.”
I don’t see the upswing attributed to investors …! Algorithms and indexes are the answer.
But, accept any upside from wherever it comes after the market spilled its milk.
It's also a ... set-up for trading the ups!
Indexes, the ebb and flow:
The iShares Russell 2000 (IWM) indicated a negative -1.18% in the pre- open and was DOWN -0.37% at the mid-day.
The iShares NASDAQ Biotechnology (IBB) indicated did NOT indicate in the pre-open and was UP at the mid-day +0.81%
Biggest losers, so far:
- Mesoblast (MESO) is down -$0.38 – after a $40 M raise – dilution causes the slip;
- Capricor (CAPR) -$0.084 – still hasn’t gotten out of its “old” ways, what’s the exosomes patent position?
- Vericel (VCEL) is down -$0.10 – trouble over sales and reimbursement issue?
- VistaGen (VTGN) is down -$0.06 – ketamine for MDD, we aren’t horses;
- BioLife Solutions (BLFS) is down -$0.035 – great sales, barely any cash other than debt;
- Biostage (BSTG) -$0.0119 – a continuing false narrative, what’s to believe as the problem of a peer reviewed publication extends beyond the promised time limit;
- Pluristem (PSTI) is down -$0.02 – false hopes for the future and a BIG dilution on the way;
- bluebird bio (BLUE) is up +$2.45 – a “raging bull” that could take a fall;
- Intrexon (XON) is up +$0.80 – what’s gone down always comes back but, for how long;
- Cellectis (CLLS) is up +$0.64 – a “bouncing betty”, don’t step too long;
- Kite Pharma (KITE) is up +$0.40 – been oversold;
- Juno Therapeutics (JUNO) is up +$0.35 – playing with the upside;
- Spark Therapeutics (ONCE) +$0.38 – always a “bouncer”;
- Applied Genetic Technologies (AGTC) at $6.65 – with approximately $8.53 per share in cash?
- AxoGen (AXGN) traded at $1.05;
- Reneuron (RENE.L) at $2.35
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.